Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
The Navy says its highest-ranking military officer has been successfully treated for early-stage breast cancer ...
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
If you or a loved one have breast cancer, you are not alone. With support groups at local hospitals and the Susan G. Komen’s ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...
The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback